PackGene Biotech, a Guangzhou-Boston company that develops viral vectors for gene therapies, completed a venture financing round from Kaitai Capital. The amount was not disclosed. The company offers customized adeno-associated virus (AAV) vector cloning/packaging services based on its unique entry vector portfolio. PackGene uses CRISPR technology to edit AAV vectors, a combination it believes will change the concept of in vivo experiments and animal modeling. It further expects its technology will solve the viral vector production bottleneck by improving the efficiency of the production process. More details.... Share this with colleagues: // //